Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
Warren writes FTC over concerns of two pharma deals, Reuters reports » 13:33
01/26/23
01/26
13:33
01/26/23
13:33
HZNP

Horizon Therapeutics

$111.63 /

-1.39 (-1.23%)

, AMGN

Amgen

$253.96 /

-2.54 (-0.99%)

, INVVY

Indivior

$25.51 /

+ (+0.00%)

, OPNT

Opiant Pharmaceuticals

$20.11 /

-0.71 (-3.41%)

Senator Elizabeth Warren…

Senator Elizabeth Warren wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals: Amgen's (AMGN) planned acquisition of Horizon Therapeutics (HZNP) and Indivior's (INVVY) plan to buy Opiant Pharmaceuticals (OPNT), Reuters reports. "Given these companies' records of anti-competitive business practices, these acquisitions could cause further price increases on lifesaving drugs and prevent affordable alternatives from entering the market," Warren wrote in the letter to FTC Chair Lina Khan as well as Commissioners Rebecca Slaughter and Alvaro Bedoya, according to Reuters. Reference Link

ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$20.11 /

-0.71 (-3.41%)

INVVY Indivior
$25.51 /

+ (+0.00%)

HZNP Horizon Therapeutics
$111.63 /

-1.39 (-1.23%)

AMGN Amgen
$253.96 /

-2.54 (-0.99%)

HZNP Horizon Therapeutics
$111.63 /

-1.39 (-1.23%)

12/19/22 Needham
Viridian Therapeutics initiated with a Buy at Needham
12/13/22 BMO Capital
Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital
12/13/22 Baird
Amgen deal yields nice accretion but large debt position, says Baird
12/13/22 Wells Fargo
Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
AMGN Amgen
$253.96 /

-2.54 (-0.99%)

01/19/23 Piper Sandler
Amgen price target cut at Piper on lower Otezla estimates
01/03/23 Barclays
Research raises 'valid questions' about Amgen's Repatha, says Barclays
INVVY Indivior
$25.51 /

+ (+0.00%)

10/24/22 Morgan Stanley
Indivior upgraded to Overweight from Equal Weight at Morgan Stanley
03/25/22 Morgan Stanley
Indivior initiated with an Equal Weight at Morgan Stanley
OPNT Opiant Pharmaceuticals
$20.11 /

-0.71 (-3.41%)

11/23/22 Northland
Opiant Pharmaceuticals downgraded to Market Perform from Outperform at Northland
11/22/22 Cantor Fitzgerald
Opiant Pharmaceuticals downgraded to Neutral at Cantor Fitzgerald
04/28/22 Northland
Northland sees 'major buying pportunity' as Opiant wraps OPNT003 clinical work
OPNT Opiant Pharmaceuticals
$20.11 /

-0.71 (-3.41%)

HZNP Horizon Therapeutics
$111.63 /

-1.39 (-1.23%)

AMGN Amgen
$253.96 /

-2.54 (-0.99%)

HZNP Horizon Therapeutics
$111.63 /

-1.39 (-1.23%)

AMGN Amgen
$253.96 /

-2.54 (-0.99%)

OPNT Opiant Pharmaceuticals
$20.11 /

-0.71 (-3.41%)

INVVY Indivior
$25.51 /

+ (+0.00%)

HZNP Horizon Therapeutics
$111.63 /

-1.39 (-1.23%)

AMGN Amgen
$253.96 /

-2.54 (-0.99%)

HZNP Horizon Therapeutics
$111.63 /

-1.39 (-1.23%)

AMGN Amgen
$253.96 /

-2.54 (-0.99%)

Over a week ago
Recommendations
Amgen price target cut at Piper on lower Otezla estimates » 06:05
01/19/23
01/19
06:05
01/19/23
06:05
AMGN

Amgen

$264.36 /

-4.88 (-1.81%)

, BMY

Bristol-Myers

$72.15 /

-0.16 (-0.22%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond lowered the firm's price target on Amgen (AMGN) to $293 from $299 and keeps an Overweight rating on the shares. New survey data makes him "increasingly concerned" that management's upbeat long-term guidance provided last year may be "unrealistic" as he is lowering his above-consensus Otezla estimates "meaningfully" given the view that Bristol-Myers' (BMY) Sotyktu is poised to take meaningful moderate-severe psoriasis patient share from Otezla in the intermediate to long term. Amgen may say that Otezla's move into the mild setting is a meaningful offset, but dermatologist projections around a shift toward Sotyktu are "too stark for us to ignore," Raymond tells investors.

ShowHide Related Items >><<
BMY Bristol-Myers
$72.15 /

-0.16 (-0.22%)

AMGN Amgen
$264.36 /

-4.88 (-1.81%)

AMGN Amgen
$264.36 /

-4.88 (-1.81%)

01/03/23 Barclays
Research raises 'valid questions' about Amgen's Repatha, says Barclays
12/13/22 BMO Capital
Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital
12/13/22 Baird
Amgen deal yields nice accretion but large debt position, says Baird
12/13/22 Wells Fargo
Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
BMY Bristol-Myers
$72.15 /

-0.16 (-0.22%)

01/17/23 Cantor Fitzgerald
Bristol-Myers initiated with an Overweight at Cantor Fitzgerald
12/23/22 William Blair
NccRCC 'material expansion opportunity' for Exelixis, says William Blair
11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
BMY Bristol-Myers
$72.15 /

-0.16 (-0.22%)

AMGN Amgen
$264.36 /

-4.88 (-1.81%)

BMY Bristol-Myers
$72.15 /

-0.16 (-0.22%)

AMGN Amgen
$264.36 /

-4.88 (-1.81%)

BMY Bristol-Myers
$72.15 /

-0.16 (-0.22%)

AMGN Amgen
$264.36 /

-4.88 (-1.81%)

BMY Bristol-Myers
$72.15 /

-0.16 (-0.22%)

AMGN Amgen
$264.36 /

-4.88 (-1.81%)

Hot Stocks
Illumina, Nashville Biosciences announce sequencing agreement with Amgen » 09:04
01/09/23
01/09
09:04
01/09/23
09:04
ILMN

Illumina

$201.94 /

+0.86 (+0.43%)

, AMGN

Amgen

$275.13 /

+8.285 (+3.10%)

Illumina (ILMN) and…

Illumina (ILMN) and Nashville Biosciences, a wholly owned subsidiary of Vanderbilt University Medical Center, announced an agreement with Amgen (AMGN) to whole-genome sequence approximately 35,000 DNA samples. The sample cohort is primarily made up of DNA from African Americans, who are currently underrepresented in research for the clinical applications of genomics, including drug target discovery. This cohort will be the largest data set of genomes of its kind to date. Sequencing this set of samples is the first in Illumina and Nashville Biosciences' Alliance for Genomic Discovery, a multiyear agreement to accelerate therapeutic development through large-scale genomics and establish a preeminent clinico-genomic data set. As part of the agreement, deCODE genetics, a wholly owned subsidiary of Amgen, will perform whole-genome sequencing on the 35,000 samples using Illumina sequencing technologies and will upload the data to the Illumina Connected Analytics platform.

ShowHide Related Items >><<
ILMN Illumina
$201.94 /

+0.86 (+0.43%)

AMGN Amgen
$275.13 /

+8.285 (+3.10%)

ILMN Illumina
$201.94 /

+0.86 (+0.43%)

01/05/23 Scotiabank
Illumina initiated with Sector Perform on Grail uncertainty Scotiabank
01/04/23 Scotiabank
Illumina initiated with a Sector Perform at Scotiabank
12/20/22 OTR Global
Illumina view upgraded to Positive from Mixed at OTR Global
12/12/22 Citi
Illumina downgraded to Sell from Neutral at Citi
AMGN Amgen
$275.13 /

+8.285 (+3.10%)

01/03/23 Barclays
Research raises 'valid questions' about Amgen's Repatha, says Barclays
12/13/22 BMO Capital
Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital
12/13/22 Baird
Amgen deal yields nice accretion but large debt position, says Baird
12/13/22 Wells Fargo
Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
ILMN Illumina
$201.94 /

+0.86 (+0.43%)

AMGN Amgen
$275.13 /

+8.285 (+3.10%)

ILMN Illumina
$201.94 /

+0.86 (+0.43%)

AMGN Amgen
$275.13 /

+8.285 (+3.10%)

ILMN Illumina
$201.94 /

+0.86 (+0.43%)

AMGN Amgen
$275.13 /

+8.285 (+3.10%)

ILMN Illumina
$201.94 /

+0.86 (+0.43%)

AMGN Amgen
$275.13 /

+8.285 (+3.10%)

Recommendations
Research raises 'valid questions' about Amgen's Repatha, says Barclays » 08:17
01/03/23
01/03
08:17
01/03/23
08:17
AMGN

Amgen

$262.69 /

-0.495 (-0.19%)

After research published…

After research published in BMJ questioned "inconsistencies" between the information in the Clinical Study Report and that in the 2017 primary trial results publication for the FOURIER trial of evolocumab, Barclays analyst Carter Gould said he suspects this recent publication "will be the first many have heard of these arguments," which in his view "raise a number of valid questions." The analyst, who sees this analysis representing "an unwelcome new narrative around a core franchise," thinks this could drive increased uncertainty around longer-term Repatha estimates, he tells investors. Gould keeps an Underweight rating and $234 price target on Amgen shares.

ShowHide Related Items >><<
AMGN Amgen
$262.69 /

-0.495 (-0.19%)

AMGN Amgen
$262.69 /

-0.495 (-0.19%)

12/13/22 BMO Capital
Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital
12/13/22 Baird
Amgen deal yields nice accretion but large debt position, says Baird
12/13/22 Wells Fargo
Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
12/13/22 Guggenheim
Horizon Therapeutics downgraded to Neutral from Buy at Guggenheim
AMGN Amgen
$262.69 /

-0.495 (-0.19%)

AMGN Amgen
$262.69 /

-0.495 (-0.19%)

AMGN Amgen
$262.69 /

-0.495 (-0.19%)

AMGN Amgen
$262.69 /

-0.495 (-0.19%)

Hot Stocks
Researchers' reanalysis questions mortality data in FOURIER trial » 08:13
01/03/23
01/03
08:13
01/03/23
08:13
AMGN

Amgen

$262.69 /

-0.495 (-0.19%)

In research published in…

In research published in BMJ, Juan Erviti, James Wright, Ken Bassett and others stated that they observed some inconsistencies between the information in the Clinical Study Report and that in the 2017 primary trial results publication for the FOURIER trial of evolocumab. In that context, they "aimed to restore the mortality data in the FOURIER trial based on the information contained in the death narratives in the CSR." The researchers conclude that after readjudication, "deaths of cardiac origin were numerically higher in the evolocumab group than in the placebo group in the FOURIER trial, suggesting possible cardiac harm." Reference Link

ShowHide Related Items >><<
AMGN Amgen
$262.69 /

-0.495 (-0.19%)

AMGN Amgen
$262.69 /

-0.495 (-0.19%)

12/13/22 BMO Capital
Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital
12/13/22 Baird
Amgen deal yields nice accretion but large debt position, says Baird
12/13/22 Wells Fargo
Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
12/13/22 Guggenheim
Horizon Therapeutics downgraded to Neutral from Buy at Guggenheim
AMGN Amgen
$262.69 /

-0.495 (-0.19%)

AMGN Amgen
$262.69 /

-0.495 (-0.19%)

AMGN Amgen
$262.69 /

-0.495 (-0.19%)

AMGN Amgen
$262.69 /

-0.495 (-0.19%)

Over a month ago
Hot Stocks
Amgen announces presentation of results from E1910 randomized Phase 3 trial » 16:03
12/13/22
12/13
16:03
12/13/22
16:03
AMGN

Amgen

$272.55 /

-4.065 (-1.47%)

Amgen announced the…

Amgen announced the ECOG-ACRIN Cancer Research Group will present results from the E1910 randomized Phase 3 trial. This is the first study to demonstrate superior overall survival, or OS, with BLINCYTO added to consolidation chemotherapy over current standard of care in newly diagnosed adult patients with Philadelphia chromosome-negative B-ALL who were measurable residual disease, or MRD,-negative following induction and intensification chemotherapy. These results were featured in a press briefing on Monday, Dec. 12 as a late breaking oral presentation, or LBA1, at the 64th American Society of Hematology, or ASH, Annual Meeting & Exposition in New Orleans. The Phase 3 randomized trial, or E1910, activated in December 2013, evaluated the safety and efficacy of BLINCYTO added to standard of care consolidation chemotherapy compared to chemotherapy alone in patients with newly diagnosed B-ALL with no MRD after induction and intensification chemotherapy. The primary endpoint was OS and key secondary endpoints included relapse-free survival, MRD status, and incidence of adverse events. Based on a recommendation by the ECOG-ACRIN Data Safety Monitoring Committee and consistent with the pre-defined efficacy threshold, results from the planned interim analysis are now reported due to overwhelming efficacy reported in the BLINCYTO arm. With a median follow up of 43 months, the study met its primary endpoint with a significant improvement in overall survival favoring the BLINCYTO arm; median OS was not reached vs. 71.4 months in the control arm. After about 3.5 years of follow-up, 83% of the patients who went on to receive additional standard consolidation chemotherapy plus experimental BLINCYTO were alive versus 65% of those who received chemotherapy only. No new safety signals were reported for the combination.

ShowHide Related Items >><<
AMGN Amgen
$272.55 /

-4.065 (-1.47%)

AMGN Amgen
$272.55 /

-4.065 (-1.47%)

12/13/22 BMO Capital
Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital
12/13/22 Baird
Amgen deal yields nice accretion but large debt position, says Baird
12/13/22 Wells Fargo
Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
12/13/22 Guggenheim
Horizon Therapeutics downgraded to Neutral from Buy at Guggenheim
AMGN Amgen
$272.55 /

-4.065 (-1.47%)

AMGN Amgen
$272.55 /

-4.065 (-1.47%)

AMGN Amgen
$272.55 /

-4.065 (-1.47%)

AMGN Amgen
$272.55 /

-4.065 (-1.47%)

On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 10:12
12/13/22
12/13
10:12
12/13/22
10:12
W

Wayfair

$41.25 /

+3.92 (+10.50%)

, Z

Zillow

$38.13 /

+2.695 (+7.61%)

, HUM

Humana

$528.24 /

-1.67 (-0.32%)

, PINS

Pinterest

$26.60 /

+2.96 (+12.52%)

, PFE

Pfizer

$53.86 /

+1.695 (+3.25%)

, MOH

Molina Healthcare

$352.36 /

-0.635 (-0.18%)

, DFS

Discover

$107.34 /

+2 (+1.90%)

, COF

Capital One

$101.70 /

+4.23 (+4.34%)

, SYF

Synchrony

$36.71 /

+1.15 (+3.23%)

, CNC

Centene

$85.22 /

-1.69 (-1.94%)

, COUP

Coupa Software

$78.60 /

+0.005 (+0.01%)

, HZNP

Horizon Therapeutics

$112.72 /

+0.41 (+0.37%)

, AMGN

Amgen

$277.14 /

+0.525 (+0.19%)

, HOOD

Robinhood

$9.98 /

+0.4 (+4.18%)

, EBAY

eBay

$45.48 /

+1.76 (+4.03%)

, ETSY

Etsy

$134.16 /

+4.61 (+3.56%)

, ZG

Zillow Group

$37.04 /

+2.61 (+7.58%)

, XMTR

Xometry

$42.50 /

+2.6 (+6.52%)

, FVRR

Fiverr

$33.88 /

+2.795 (+8.99%)

, CVNA

Carvana

$5.29 /

+0.345 (+6.98%)

, CARG

CarGurus

$14.07 /

+1.015 (+7.77%)

, LAD

Lithia & Driveway

$225.58 /

+3.41 (+1.53%)

, UPWK

Upwork

$12.34 /

+0.875 (+7.63%)

, LITE

Lumentum

$56.51 /

+2.06 (+3.78%)

, MBLY

Mobileye

$34.21 /

+1.13 (+3.42%)

, WSM

Williams-Sonoma

$122.36 /

+5.63 (+4.82%)

, RH

RH

$265.50 /

+11.85 (+4.67%)

, EQIX

Equinix

$710.33 /

+31.04 (+4.57%)

Institutional investors…

ShowHide Related Items >><<
ZG Zillow Group
$37.04 /

+2.61 (+7.58%)

Z Zillow
$38.13 /

+2.695 (+7.61%)

XMTR Xometry
$42.50 /

+2.6 (+6.52%)

WSM Williams-Sonoma
$122.36 /

+5.63 (+4.82%)

W Wayfair
$41.25 /

+3.92 (+10.50%)

UPWK Upwork
$12.34 /

+0.875 (+7.63%)

SYF Synchrony
$36.71 /

+1.15 (+3.23%)

RH RH
$265.50 /

+11.85 (+4.67%)

PINS Pinterest
$26.60 /

+2.96 (+12.52%)

PFE Pfizer
$53.86 /

+1.695 (+3.25%)

MOH Molina Healthcare
$352.36 /

-0.635 (-0.18%)

MBLY Mobileye
$34.21 /

+1.13 (+3.42%)

LITE Lumentum
$56.51 /

+2.06 (+3.78%)

LAD Lithia & Driveway
$225.58 /

+3.41 (+1.53%)

HZNP Horizon Therapeutics
$112.72 /

+0.41 (+0.37%)

HUM Humana
$528.24 /

-1.67 (-0.32%)

HOOD Robinhood
$9.98 /

+0.4 (+4.18%)

FVRR Fiverr
$33.88 /

+2.795 (+8.99%)

ETSY Etsy
$134.16 /

+4.61 (+3.56%)

EQIX Equinix
$710.33 /

+31.04 (+4.57%)

EBAY eBay
$45.48 /

+1.76 (+4.03%)

DFS Discover
$107.34 /

+2 (+1.90%)

CVNA Carvana
$5.29 /

+0.345 (+6.98%)

COUP Coupa Software
$78.60 /

+0.005 (+0.01%)

COF Capital One
$101.70 /

+4.23 (+4.34%)

CNC Centene
$85.22 /

-1.69 (-1.94%)

CARG CarGurus
$14.07 /

+1.015 (+7.77%)

AMGN Amgen
$277.14 /

+0.525 (+0.19%)

W Wayfair
$41.25 /

+3.92 (+10.50%)

12/13/22 Citi
Wayfair initiated with a Buy at Citi
11/30/22 Stephens
Wayfair five-day holiday sales report implies upside to consensus, says Stephens
11/21/22 Cowen
Cowen downgrades Wayfair on home consumer demand concerns
11/21/22 Cowen
Wayfair downgraded to Market Perform from Outperform at Cowen
Z Zillow
$38.13 /

+2.695 (+7.61%)

12/13/22 Citi
Zillow Group initiated with a Buy at Citi
11/04/22 Evercore ISI
Zillow Group removed from 'Tactical Underperform' list at Evercore ISI
11/03/22 Canaccord
Zillow Group downgraded to Hold on macro pressures at Canaccord
11/03/22 Canaccord
Zillow Group downgraded to Hold from Buy at Canaccord
HUM Humana
$528.24 /

-1.67 (-0.32%)

12/13/22 Goldman Sachs
Humana upgraded to Buy at Goldman Sachs on improved competitive position
12/13/22 Goldman Sachs
Humana upgraded to Buy from Neutral at Goldman Sachs
12/01/22 Craig-Hallum
Craig-Hallum upgrades eHealth to Buy on 'clear signs of life'
11/08/22 Wells Fargo
Humana price target raised to $610 from $558 at Wells Fargo
PINS Pinterest
$26.60 /

+2.96 (+12.52%)

12/13/22 Piper Sandler
Pinterest upgraded to Overweight from Neutral at Piper Sandler
10/31/22 Citi
Pinterest price target raised to $26 from $25 at Citi
10/28/22 Stifel
Pinterest 'a rare bright spot thus far through earnings,' says Stifel
10/28/22 Barclays
Pinterest price target raised to $25 from $23 at Barclays
PFE Pfizer
$53.86 /

+1.695 (+3.25%)

12/13/22 Piper Sandler
Takeda deal has positive read through for Ventyx, says Piper
12/13/22 Goldman Sachs
Goldman upgrades Pfizer to Buy on pipeline, new launch upside
12/13/22 Goldman Sachs
Pfizer upgraded to Buy from Neutral at Goldman Sachs
12/07/22 Piper Sandler
Prometheus price target raised to $114 from $67 at Piper Sandler
MOH Molina Healthcare
$352.36 /

-0.635 (-0.18%)

12/13/22 BofA
Molina Healthcare upgraded to Neutral at BofA on 'high confidence' in EPS growth
12/13/22 BofA
Molina Healthcare upgraded to Neutral from Underperform at BofA
11/07/22 Cowen
Molina Healthcare price target raised to $380 from $371 at Cowen
11/01/22 Deutsche Bank
Molina Healthcare price target raised to $355 from $315 at Deutsche Bank
DFS Discover
$107.34 /

+2 (+1.90%)

12/13/22 BofA
Synchrony downgraded to Neutral at BofA on consumer concerns
12/13/22 BofA
Discover double downgraded to Underperform at BofA on consumer concerns
12/13/22 BofA
Discover downgraded to Underperform from Buy at BofA
11/21/22 UBS
Discover initiated with a Neutral at UBS
COF Capital One
$101.70 /

+4.23 (+4.34%)

12/12/22 JPMorgan
Capital One added to Analyst Focus List at JPMorgan
12/01/22 Wolfe Research
Capital One price target raised to $81 from $77 at Wolfe Research
SYF Synchrony
$36.71 /

+1.15 (+3.23%)

12/13/22 BofA
Synchrony downgraded to Neutral from Buy at BofA
12/01/22 Morgan Stanley
Synchrony downgraded to Underweight from Equal Weight at Morgan Stanley
CNC Centene
$85.22 /

-1.69 (-1.94%)

12/13/22 BofA
Centene downgraded to Underperform from Neutral at BofA
11/23/22 Morgan Stanley
CVS Health assumed with an Overweight at Morgan Stanley
11/18/22 Cowen
Evolent Health price target raised to $57 from $52 at Cowen
11/18/22 Piper Sandler
Piper says buy Evolent Health following Magellan Specialty deal
COUP Coupa Software
$78.60 /

+0.005 (+0.01%)

12/13/22 Raymond James
Coupa Software downgraded to Market Perform from Outperform at Raymond James
12/13/22 DA Davidson
Coupa Software price target raised to $81 from $50 at DA Davidson
12/13/22 Needham
Coupa Software downgraded to Hold from Buy at Needham
12/13/22 Wells Fargo
Coupa Software price target raised to $81 from $65 at Wells Fargo
HZNP Horizon Therapeutics
$112.72 /

+0.41 (+0.37%)

12/13/22 BMO Capital
Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital
12/13/22 Baird
Amgen deal yields nice accretion but large debt position, says Baird
12/13/22 Wells Fargo
Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
12/13/22 Guggenheim
Horizon Therapeutics downgraded to Neutral from Buy at Guggenheim
AMGN Amgen
$277.14 /

+0.525 (+0.19%)

HOOD Robinhood
$9.98 /

+0.4 (+4.18%)

12/12/22 Citi
Robinhood downgraded to Neutral from Buy at Citi
12/12/22 Mizuho
Fiserv price target lowered to $135 from $145 at Mizuho
12/02/22 Piper Sandler
Piper calls for 'more aggressive headcount reduction' at Coinbase
11/15/22 Deutsche Bank
Robinhood price target lowered to $9 from $11 at Deutsche Bank
EBAY eBay
$45.48 /

+1.76 (+4.03%)

12/13/22 Citi
eBay initiated with a Neutral at Citi
12/05/22
eBay participates in a conference call with Mizuho
11/15/22 MoffettNathanson
eBay initiated with a Market Perform at MoffettNathanson
11/03/22 Benchmark
eBay price target lowered to $62 from $66 at Benchmark
ETSY Etsy
$134.16 /

+4.61 (+3.56%)

12/13/22 Citi
Etsy initiated with a Buy at Citi
12/06/22 BofA
Etsy price target raised to $145 from $110 at BofA
12/01/22 BTIG
Etsy price target raised to $137 from $119 at BTIG
11/16/22 Evercore ISI
Etsy added to 'Tactical Underperform' list at Evercore ISI
ZG Zillow Group
$37.04 /

+2.61 (+7.58%)

12/02/22 UBS
Zillow Group initiated with a Buy at UBS
11/07/22 Truist
Zillow Group price target lowered to $34 from $37 at Truist
XMTR Xometry
$42.50 /

+2.6 (+6.52%)

12/13/22 Citi
Xometry initiated with a Buy at Citi
11/11/22 UBS
Xometry price target lowered to $45 from $55 at UBS
08/24/22 JPMorgan
JPMorgan cuts Xometry target but still sees 46% upside potential
08/24/22 JPMorgan
Xometry price target lowered to $65 from $100 at JPMorgan
FVRR Fiverr
$33.88 /

+2.795 (+8.99%)

12/13/22 Citi
Fiverr initiated with a Buy at Citi
11/10/22 Oppenheimer
Fiverr price target lowered to $40 from $50 at Oppenheimer
11/09/22 Piper Sandler
Fiverr margin expansion story 'very much on track,' says Piper Sandler
08/05/22 Needham
Fiverr price target raised to $50 from $40 at Needham
CVNA Carvana
$5.29 /

+0.345 (+6.98%)

12/13/22 Citi
Carvana initiated with a Neutral at Citi
12/09/22 Jefferies
Vroom price target lowered to $1.10 from $1.30 at Jefferies
12/09/22 Jefferies
Carvana price target lowered to $5 from $10 at Jefferies
12/09/22 Needham
Needham downgrades Carvana, struggles to see near-term path forward
CARG CarGurus
$14.07 /

+1.015 (+7.77%)

12/13/22 Citi
CarGurus initiated with a Neutral at Citi
11/10/22 DA Davidson
CarGurus price target lowered to $11.50 from $30 at DA Davidson
11/10/22 Oppenheimer
CarGurus price target lowered to $16 from $26 at Oppenheimer
11/09/22 BTIG
CarGurus price target lowered to $19 from $25 at BTIG
LAD Lithia & Driveway
$225.58 /

+3.41 (+1.53%)

12/13/22 Citi
Lithia & Driveway initiated with a Neutral at Citi
10/26/22 Morgan Stanley
Lithia & Driveway price target lowered to $200 from $220 at Morgan Stanley
10/21/22 Benchmark
Lithia & Driveway price target lowered to $300 from $400 at Benchmark
10/20/22 Craig-Hallum
Lithia & Driveway price target lowered to $360 from $540 at Craig-Hallum
UPWK Upwork
$12.34 /

+0.875 (+7.63%)

12/13/22 Citi
Upwork initiated with a Neutral at Citi
10/27/22 RBC Capital
Upwork price target lowered to $15 from $21 at RBC Capital
10/27/22 Needham
Upwork price target lowered to $19 from $27 at Needham
10/27/22 Canaccord
Upwork price target lowered to $25 from $36 at Canaccord
LITE Lumentum
$56.51 /

+2.06 (+3.78%)

12/13/22 Morgan Stanley
Lumentum price target lowered to $66 from $75 at Morgan Stanley
12/13/22 UBS
Lumentum initiated with a Neutral at UBS
12/01/22 Stifel
Lumentum initiated with a Buy at Stifel
11/11/22 BofA
Lumentum downgraded to Neutral at BofA on mounting headwinds
MBLY Mobileye
$34.21 /

+1.13 (+3.42%)

12/13/22 JPMorgan
Mobileye initiated with an Overweight at JPMorgan
12/08/22 Baird
Mobileye price target raised to $39 from $36 at Baird
12/05/22 Tigress Financial
Mobileye initiated with a Buy at Tigress Financial
12/01/22 New Street
Mobileye initiated with a Buy at New Street
WSM Williams-Sonoma
$122.36 /

+5.63 (+4.82%)

12/13/22 Needham
Williams-Sonoma initiated with a Hold at Needham
11/28/22 Morgan Stanley
Williams-Sonoma downgraded to Underweight from Equal Weight at Morgan Stanley
11/21/22 Barclays
Williams-Sonoma downgraded to Equal Weight from Overweight at Barclays
11/21/22 Barclays
RH downgraded to Equal Weight from Overweight at Barclays
RH RH
$265.50 /

+11.85 (+4.67%)

12/12/22 Cowen
RH price target lowered to $320 from $350 at Cowen
12/12/22 Loop Capital
RH price target lowered to $370 from $420 at Loop Capital
12/12/22 Barclays
RH price target raised to $254 from $243 at Barclays
EQIX Equinix
$710.33 /

+31.04 (+4.57%)

12/13/22 Cowen
Equinix upgraded to Outperform from Market Perform at Cowen
11/17/22 Deutsche Bank
Equinix price target raised to $680 from $635 at Deutsche Bank
11/14/22 RBC Capital
Equinix price target raised to $720 from $668 at RBC Capital
11/13/22 Citi
Equinix price target lowered to $750 from $810 at Citi
Z Zillow
$38.13 /

+2.695 (+7.61%)

XMTR Xometry
$42.50 /

+2.6 (+6.52%)

WSM Williams-Sonoma
$122.36 /

+5.63 (+4.82%)

W Wayfair
$41.25 /

+3.92 (+10.50%)

UPWK Upwork
$12.34 /

+0.875 (+7.63%)

SYF Synchrony
$36.71 /

+1.15 (+3.23%)

RH RH
$265.50 /

+11.85 (+4.67%)

PINS Pinterest
$26.60 /

+2.96 (+12.52%)

PFE Pfizer
$53.86 /

+1.695 (+3.25%)

MOH Molina Healthcare
$352.36 /

-0.635 (-0.18%)

MBLY Mobileye
$34.21 /

+1.13 (+3.42%)

LITE Lumentum
$56.51 /

+2.06 (+3.78%)

LAD Lithia & Driveway
$225.58 /

+3.41 (+1.53%)

HZNP Horizon Therapeutics
$112.72 /

+0.41 (+0.37%)

HUM Humana
$528.24 /

-1.67 (-0.32%)

HOOD Robinhood
$9.98 /

+0.4 (+4.18%)

FVRR Fiverr
$33.88 /

+2.795 (+8.99%)

ETSY Etsy
$134.16 /

+4.61 (+3.56%)

EQIX Equinix
$710.33 /

+31.04 (+4.57%)

EBAY eBay
$45.48 /

+1.76 (+4.03%)

DFS Discover
$107.34 /

+2 (+1.90%)

CVNA Carvana
$5.29 /

+0.345 (+6.98%)

COUP Coupa Software
$78.60 /

+0.005 (+0.01%)

COF Capital One
$101.70 /

+4.23 (+4.34%)

CNC Centene
$85.22 /

-1.69 (-1.94%)

CARG CarGurus
$14.07 /

+1.015 (+7.77%)

AMGN Amgen
$277.14 /

+0.525 (+0.19%)

  • 26
    Oct
  • 22
    Apr
Z Zillow
$38.13 /

+2.695 (+7.61%)

W Wayfair
$41.25 /

+3.92 (+10.50%)

SYF Synchrony
$36.71 /

+1.15 (+3.23%)

PINS Pinterest
$26.60 /

+2.96 (+12.52%)

PFE Pfizer
$53.86 /

+1.695 (+3.25%)

MOH Molina Healthcare
$352.36 /

-0.635 (-0.18%)

MBLY Mobileye
$34.21 /

+1.13 (+3.42%)

HZNP Horizon Therapeutics
$112.72 /

+0.41 (+0.37%)

HUM Humana
$528.24 /

-1.67 (-0.32%)

HOOD Robinhood
$9.98 /

+0.4 (+4.18%)

FVRR Fiverr
$33.88 /

+2.795 (+8.99%)

ETSY Etsy
$134.16 /

+4.61 (+3.56%)

EQIX Equinix
$710.33 /

+31.04 (+4.57%)

EBAY eBay
$45.48 /

+1.76 (+4.03%)

CVNA Carvana
$5.29 /

+0.345 (+6.98%)

COUP Coupa Software
$78.60 /

+0.005 (+0.01%)

COF Capital One
$101.70 /

+4.23 (+4.34%)

AMGN Amgen
$277.14 /

+0.525 (+0.19%)

Z Zillow
$38.13 /

+2.695 (+7.61%)

XMTR Xometry
$42.50 /

+2.6 (+6.52%)

WSM Williams-Sonoma
$122.36 /

+5.63 (+4.82%)

W Wayfair
$41.25 /

+3.92 (+10.50%)

UPWK Upwork
$12.34 /

+0.875 (+7.63%)

RH RH
$265.50 /

+11.85 (+4.67%)

PINS Pinterest
$26.60 /

+2.96 (+12.52%)

PFE Pfizer
$53.86 /

+1.695 (+3.25%)

MOH Molina Healthcare
$352.36 /

-0.635 (-0.18%)

MBLY Mobileye
$34.21 /

+1.13 (+3.42%)

LITE Lumentum
$56.51 /

+2.06 (+3.78%)

HUM Humana
$528.24 /

-1.67 (-0.32%)

HOOD Robinhood
$9.98 /

+0.4 (+4.18%)

ETSY Etsy
$134.16 /

+4.61 (+3.56%)

EQIX Equinix
$710.33 /

+31.04 (+4.57%)

EBAY eBay
$45.48 /

+1.76 (+4.03%)

DFS Discover
$107.34 /

+2 (+1.90%)

CVNA Carvana
$5.29 /

+0.345 (+6.98%)

COUP Coupa Software
$78.60 /

+0.005 (+0.01%)

COF Capital One
$101.70 /

+4.23 (+4.34%)

CNC Centene
$85.22 /

-1.69 (-1.94%)

CARG CarGurus
$14.07 /

+1.015 (+7.77%)

AMGN Amgen
$277.14 /

+0.525 (+0.19%)

Z Zillow
$38.13 /

+2.695 (+7.61%)

WSM Williams-Sonoma
$122.36 /

+5.63 (+4.82%)

W Wayfair
$41.25 /

+3.92 (+10.50%)

SYF Synchrony
$36.71 /

+1.15 (+3.23%)

RH RH
$265.50 /

+11.85 (+4.67%)

PINS Pinterest
$26.60 /

+2.96 (+12.52%)

PFE Pfizer
$53.86 /

+1.695 (+3.25%)

MOH Molina Healthcare
$352.36 /

-0.635 (-0.18%)

MBLY Mobileye
$34.21 /

+1.13 (+3.42%)

HZNP Horizon Therapeutics
$112.72 /

+0.41 (+0.37%)

HUM Humana
$528.24 /

-1.67 (-0.32%)

HOOD Robinhood
$9.98 /

+0.4 (+4.18%)

ETSY Etsy
$134.16 /

+4.61 (+3.56%)

EQIX Equinix
$710.33 /

+31.04 (+4.57%)

EBAY eBay
$45.48 /

+1.76 (+4.03%)

DFS Discover
$107.34 /

+2 (+1.90%)

CVNA Carvana
$5.29 /

+0.345 (+6.98%)

COUP Coupa Software
$78.60 /

+0.005 (+0.01%)

COF Capital One
$101.70 /

+4.23 (+4.34%)

CNC Centene
$85.22 /

-1.69 (-1.94%)

CARG CarGurus
$14.07 /

+1.015 (+7.77%)

AMGN Amgen
$277.14 /

+0.525 (+0.19%)

Downgrade
Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital » 07:34
12/13/22
12/13
07:34
12/13/22
07:34
HZNP

Horizon Therapeutics

$112.34 /

+14.995 (+15.40%)

, AMGN

Amgen

$276.76 /

-1.825 (-0.66%)

BMO Capital analyst Gary…

BMO Capital analyst Gary Nachman downgraded Horizon Therapeutics (HZNP) to Market Perform from Outperform with a $117 price target. The company's acquisition by Amgen (AMGN) reflects a fair value for a "solid growth story" and he does not anticipate any major hurdles from the standpoint of the FTC, the analyst tells investors in a research note.

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

12/13/22 Baird
Amgen deal yields nice accretion but large debt position, says Baird
12/13/22 Wells Fargo
Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
12/13/22 Guggenheim
Horizon Therapeutics downgraded to Neutral from Buy at Guggenheim
12/12/22 Piper Sandler
Amgen price target raised to $299 from $297 at Piper Sandler
AMGN Amgen
$276.76 /

-1.825 (-0.66%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

Recommendations
Amgen deal yields nice accretion but large debt position, says Baird » 06:56
12/13/22
12/13
06:56
12/13/22
06:56
AMGN

Amgen

$276.76 /

-1.825 (-0.66%)

, HZNP

Horizon Therapeutics

$112.34 /

+14.995 (+15.40%)

Baird analyst Brian…

Baird analyst Brian Skorney said the Amgen (AMGN) acquisition of Horizon Therapeutics (HZNP) yields some nice near term accretion but the sizeable debt position and bidding war keeps him cautious. He said the company will be sitting on one of the largest debt positions in the sector and with competitors all bowing out of the process, the deal may be more optical benefit on EPS than positive ROI. Skorney maintains his Underperform rating and $185 price target on Amgen shares.

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

12/13/22 Wells Fargo
Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
12/13/22 Guggenheim
Horizon Therapeutics downgraded to Neutral from Buy at Guggenheim
12/12/22 Piper Sandler
Amgen price target raised to $299 from $297 at Piper Sandler
12/12/22 Wells Fargo
Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargpo
HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

Downgrade
Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo » 06:46
12/13/22
12/13
06:46
12/13/22
06:46
HZNP

Horizon Therapeutics

$112.34 /

+14.995 (+15.40%)

, AMGN

Amgen

$276.76 /

-1.825 (-0.66%)

Wells Fargo analyst Derek…

Wells Fargo analyst Derek Archila downgraded Horizon Therapeutics (HZNP) to Equal Weight from Overweight with a price target of $116.50, down from $118, after Amgen (AMGN) announced an agreement to acquire the company for $116.50/share, valuing the company at about $28B. The analyst thinks the deal makes sense and is consistent with his view that Horizon Therapeutics' management was a willing and motivated seller. Given the deal process and the looks by other companies, Archila doesn't think anyone else is "going to throw their hat in the ring" and sees a high probability of the deal getting done.

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

12/13/22 Guggenheim
Horizon Therapeutics downgraded to Neutral from Buy at Guggenheim
12/12/22 Piper Sandler
Amgen price target raised to $299 from $297 at Piper Sandler
12/12/22 Wells Fargo
Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargpo
12/12/22 Piper Sandler
Horizon Therapeutics downgraded to Neutral from Overweight at Piper Sandler
AMGN Amgen
$276.76 /

-1.825 (-0.66%)

12/12/22 Stifel
Horizon Therapeutics downgraded to Hold from Buy at Stifel
HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

HZNP Horizon Therapeutics
$112.34 /

+14.995 (+15.40%)

AMGN Amgen
$276.76 /

-1.825 (-0.66%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.